Ruben Mesa, M.D.

Dr. Ruben Mesa is an international expert in hematologic cancers. He has dedicated his life‘s work to research and drug development for myeloproliferative neoplasms (MPNs). His research focuses on MPN biology, novel therapeutics and over 100 phase I-III clinical trials, symptom assessment tools and non- pharmacological interventions to alleviate MPN symptoms. He has led or co-led the development of 6 drugs that have been FDA-approved for MPNs. He serves in various leadership roles with the American Society of Hematology (ASH) and the American Association of Cancer Research (AACR). He has been elected to the board of the Association of American Cancer Institutes (AACI) and is an executive officer of the board for the Leukemia & Lymphoma Society.

Dr. Mesa has over 800 lifetime medical publications, with more than 500 peer-reviewed manuscripts, 15 book chapters and 2 edited books. He is frequently invited to speak on MPNs with over 600 lectures and visiting professorships, nationally and internationally.